Embecta Corp. (NASDAQ:EMBC) Plans Quarterly Dividend of $0.01

Embecta Corp. (NASDAQ:EMBC) announced a quarterly dividend on Friday, May 1st. Stockholders of record on Thursday, May 28th will be paid a dividend of 0.01 per share on Monday, June 15th. This represents a c) dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Thursday, May 28th.

Embecta has a payout ratio of 1.4% meaning its dividend is sufficiently covered by earnings. Research analysts expect Embecta to earn $1.75 per share next year, which means the company should continue to be able to cover its $0.04 annual dividend with an expected future payout ratio of 2.3%.

Embecta Price Performance

Shares of EMBC opened at $3.32 on Tuesday. The company has a market cap of $196.98 million, a P/E ratio of 1.75 and a beta of 1.09. The stock has a fifty day moving average price of $7.33 and a 200 day moving average price of $10.16. Embecta has a 12 month low of $2.77 and a 12 month high of $15.55.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). The company had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.Embecta’s quarterly revenue was down 14.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.70 earnings per share. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, research analysts anticipate that Embecta will post 1.62 earnings per share for the current year.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.